Skip to main content
Clinical Trials/NCT05247255
NCT05247255
Recruiting
Early Phase 1

Quadratus Lumborum (QL) Nerve Block for Patients Undergoing Primary Total Hip Arthroplasty (THA)

University of California, Los Angeles1 site in 1 country80 target enrollmentMarch 29, 2022

Overview

Phase
Early Phase 1
Intervention
Active Comparator
Conditions
Pain, Postoperative
Sponsor
University of California, Los Angeles
Enrollment
80
Locations
1
Primary Endpoint
Pain score
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The quadratus lumborum (QL) block is a fascial plane block that has been described to provide analgesia from T7-L3 dermatomes. The investigators aim to evaluate the efficacy of QL blocks in patients undergoing primary total hip arthroplasty (THA).

Detailed Description

Investigators will enroll subjects planned for primary THA and allocate them into receiving a QL block with either saline or ropivacaine. Primary outcome will be pain scores over the first 48 hours after surgery.

Registry
clinicaltrials.gov
Start Date
March 29, 2022
End Date
January 1, 2027
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Pamela Chia

HS Assistant Professor

University of California, Los Angeles

Eligibility Criteria

Inclusion Criteria

  • Adult subjects undergoing elective primary total hip arthroplasty

Exclusion Criteria

  • patients age \< 18,
  • documented allergy to local anesthetic
  • presence of peripheral neuropathy
  • patients with current long term opioid use defined as receiving an opioid on most days in a 90 day period
  • patients with a contraindication to spinal and regional anesthesia such as coagulopathy or infection at the site of the regional technique.

Arms & Interventions

Intervention Group

Quadratus lumborum nerve block with 0.25% ropivacaine

Intervention: Active Comparator

Control Group

Quadratus lumborum nerve block with saline

Intervention: Placebo Comparator

Outcomes

Primary Outcomes

Pain score

Time Frame: Up to 48 hrs post op

Pain scores will be assessed over 48hrs postop using the visual analog score

Secondary Outcomes

  • Time to first ambulation(Up to 1 week post surgery)
  • Ambulation distance(Up to 1 week post surgery)
  • Patient satisfaction(Until day of discharge from the hospital, up to 1 week post surgery)
  • Opioid usage(Up to 48 hrs post op)
  • Time to first stand(Up to 1 week post surgery)
  • Length of hospital stay(Until discharge from hospital, up to 1 week post surgery)

Study Sites (1)

Loading locations...

Similar Trials